Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 262.93 USD 0.35% Market Closed
Market Cap: 18.4B USD
Have any thoughts about
Insulet Corp?
Write Note

Intrinsic Value

The intrinsic value of one PODD stock under the Base Case scenario is 96.69 USD. Compared to the current market price of 262.93 USD, Insulet Corp is Overvalued by 63%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PODD Intrinsic Value
96.69 USD
Overvaluation 63%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Insulet Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PODD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PODD?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Insulet Corp

Provide an overview of the primary business activities
of Insulet Corp.

What unique competitive advantages
does Insulet Corp hold over its rivals?

What risks and challenges
does Insulet Corp face in the near future?

Has there been any significant insider trading activity
in Insulet Corp recently?

Summarize the latest earnings call
of Insulet Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Insulet Corp.

Provide P/S
for Insulet Corp.

Provide P/E
for Insulet Corp.

Provide P/OCF
for Insulet Corp.

Provide P/FCFE
for Insulet Corp.

Provide P/B
for Insulet Corp.

Provide EV/S
for Insulet Corp.

Provide EV/GP
for Insulet Corp.

Provide EV/EBITDA
for Insulet Corp.

Provide EV/EBIT
for Insulet Corp.

Provide EV/OCF
for Insulet Corp.

Provide EV/FCFF
for Insulet Corp.

Provide EV/IC
for Insulet Corp.

Show me price targets
for Insulet Corp made by professional analysts.

What are the Revenue projections
for Insulet Corp?

How accurate were the past Revenue estimates
for Insulet Corp?

What are the Net Income projections
for Insulet Corp?

How accurate were the past Net Income estimates
for Insulet Corp?

What are the EPS projections
for Insulet Corp?

How accurate were the past EPS estimates
for Insulet Corp?

What are the EBIT projections
for Insulet Corp?

How accurate were the past EBIT estimates
for Insulet Corp?

Compare the revenue forecasts
for Insulet Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Insulet Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Insulet Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Insulet Corp compared to its peers.

Compare the P/E ratios
of Insulet Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Insulet Corp with its peers.

Analyze the financial leverage
of Insulet Corp compared to its main competitors.

Show all profitability ratios
for Insulet Corp.

Provide ROE
for Insulet Corp.

Provide ROA
for Insulet Corp.

Provide ROIC
for Insulet Corp.

Provide ROCE
for Insulet Corp.

Provide Gross Margin
for Insulet Corp.

Provide Operating Margin
for Insulet Corp.

Provide Net Margin
for Insulet Corp.

Provide FCF Margin
for Insulet Corp.

Show all solvency ratios
for Insulet Corp.

Provide D/E Ratio
for Insulet Corp.

Provide D/A Ratio
for Insulet Corp.

Provide Interest Coverage Ratio
for Insulet Corp.

Provide Altman Z-Score Ratio
for Insulet Corp.

Provide Quick Ratio
for Insulet Corp.

Provide Current Ratio
for Insulet Corp.

Provide Cash Ratio
for Insulet Corp.

What is the historical Revenue growth
over the last 5 years for Insulet Corp?

What is the historical Net Income growth
over the last 5 years for Insulet Corp?

What is the current Free Cash Flow
of Insulet Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Insulet Corp.

Business Breakdown

Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant ma...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Insulet Corp

Current Assets 1.9B
Cash & Short-Term Investments 795.6m
Receivables 375.6m
Other Current Assets 689.7m
Non-Current Assets 1.2B
PP&E 702.9m
Intangibles 151.3m
Other Non-Current Assets 310.3m
Current Liabilities 506.2m
Accounts Payable 40.3m
Accrued Liabilities 423.9m
Other Current Liabilities 42m
Non-Current Liabilities 1.4B
Long-Term Debt 1.4B
Other Non-Current Liabilities 44.9m
Efficiency

Earnings Waterfall
Insulet Corp

Revenue
2B USD
Cost of Revenue
-607.9m USD
Gross Profit
1.4B USD
Operating Expenses
-1.1B USD
Operating Income
306m USD
Other Expenses
114.9m USD
Net Income
420.9m USD

Free Cash Flow Analysis
Insulet Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Insulet Corporation reported a robust 25% revenue growth in Q3, propelled by a 26% rise in Omnipod sales. U.S. revenue grew by 23%, nearing the high end of guidance, with international growth reaching an impressive 35%. Following the FDA clearance to expand the Omnipod 5 label to type 2 diabetes, new customer starts surged. For Q4, Insulet expects a total Omnipod growth of 13% to 16%, forecasting full-year revenue exceeding $2 billion. The company anticipates ongoing margin improvements, with a gross margin near 69% and operating margins adjusted upwards to 14.5%.

What is Earnings Call?
Fundamental Scores

PODD Profitability Score
Profitability Due Diligence

Insulet Corp's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROE
Exceptional 3-Years Revenue Growth
ROE is Increasing
64/100
Profitability
Score

Insulet Corp's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

PODD Solvency Score
Solvency Due Diligence

Insulet Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
67/100
Solvency
Score

Insulet Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PODD Price Targets Summary
Insulet Corp

Wall Street analysts forecast PODD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PODD is 282.11 USD with a low forecast of 236.34 USD and a high forecast of 332.85 USD.

Lowest
Price Target
236.34 USD
10% Downside
Average
Price Target
282.11 USD
7% Upside
Highest
Price Target
332.85 USD
27% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PODD?

Click here to dive deeper.

Dividends

Insulet Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for PODD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PODD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

PODD News

Other Videos

Profile

Insulet Corp Logo
Insulet Corp

Country

United States of America

Industry

Health Care

Market Cap

18.4B USD

Dividend Yield

0%

Description

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 2,300 full-time employees. The company went IPO on 2007-05-15. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. The company can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.

Contact

MASSACHUSETTS
Acton
100 Nagog Park
+19786007000.0
www.omnipod.com

IPO

2007-05-15

Employees

2 300

Officers

President, CEO & Director
Dr. James R. Hollingshead Ph.D.
Group VP, Chief Accounting Officer & Controller
Ms. Lauren Budden
Senior VP & CTO
Mr. Mark Field
Senior VP & General Counsel
Mr. John Wodick Kapples
Executive VP, Chief Product & Customer Experience Officer
Mr. Eric Benjamin
Executive VP, CFO & Treasurer
Ms. Ana Maria Chadwick
Show More
Senior Vice President of Global Operations
Mr. Prem Singh
Vice President of Investor Relations
Ms. Deborah R. Gordon CPA
Senior VP of Regulatory Affairs, Quality Assurance & Compliance
Ms. Laetitia Cousin
Senior Director of Corporate Communications
Angela Geryak Wiczek
Show Less

See Also

Discover More
What is the Intrinsic Value of one PODD stock?

The intrinsic value of one PODD stock under the Base Case scenario is 96.69 USD.

Is PODD stock undervalued or overvalued?

Compared to the current market price of 262.93 USD, Insulet Corp is Overvalued by 63%.

Back to Top